In preclinical studies, pictilisib had antitumor activity in breast cancer models harboring PIK3CA mutations and/or amplification of HER2, although several models without these mutations were also sensitive to pictilisib treatment [24]. This evidence concerns the gene ERBB2 and breast carcinoma.